[1]石佳鹏,汤小星,顾祝新,等.TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期肝细胞癌的临床研究[J].介入放射学杂志,2024,33(09):995-1000.
　SHI Jiapeng,TANG Xiaoxing,GU Zhuxin,et al.TACE combined with regorafenib and PD-1 second-line sequential therapy for advanced hepatocellular carcinoma：a clinical study[J].journal interventional radiology,2024,33(09):995-1000.
点击复制

TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期肝细胞癌的临床研究()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
33
期数:
2024年09
页码:
995-1000
栏目:
临床研究
出版日期:
2024-09-17

文章信息/Info

Title:
TACE combined with regorafenib and PD-1 second-line sequential therapy for advanced hepatocellular carcinoma：a clinical study
作者:
石佳鹏; 汤小星; 顾祝新; 施荣峰; 陆小华; 赵辉
Author(s):
SHI Jiapeng; TANG Xiaoxing; GU Zhuxin; SHI Rongfeng; LU Xiaohua; ZHAO Hui.
Interventional Department of Nantong Traditional Chinese Medicine Hospital，Nantong，Jiangsu Province 226001，China
关键词:
【关键词】肝细胞癌; TACE; 瑞戈非尼; PD-1; 临床疗效; 安全性
文献标志码:
A
摘要:
【摘要】目的探讨TACE联合瑞戈非尼及程序性死亡受体（PD-1）二线序贯治疗中晚期肝细胞癌（HCC）的有效性和安全性。方法纳入南通大学附属医院及南通市第三人民医院2020年10月至2022年5月所有接受TACE联合瑞戈非尼及PD-1（TACE-RP，三联组）和接受TACE联合瑞戈非尼治疗（TACE-R，二联组）的患者进行回顾性研究，共83例。收集、评估患者的临床资料，采用改良的实体瘤反应评估标准（mRECIST方法）评估治疗效果，比较两组患者无进展生存期（PFS）、总生存期（OS）以及治疗相关不良事件（TRAEs）。以Kaplan-Meier法绘制PFS及OS曲线，采用Log-rank检验进行组间比较，绘制COX回归模型确定PFS和OS的影响因素。结果两组患者基线数据差异无统计学意义（P≥0.05）；三联组患者客观缓解率（ORR，31.1% vs 18.4%，P=0.024）和疾病控制率（DCR，77.8% vs 57.8%，P=0.038）均高于二联组。三联组患者的mOS、mPFS均高于二联组（分别为16.80个月vs13.20个月，9.10个月vs 7.40个月）。两组间用药不良反应差异无统计学意义（P≥0.05）。结论TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期HCC较TACE联合瑞戈非尼治疗效果更佳，可优先作为HCC的二线治疗。

参考文献/References:

［1］Zhou J，Sun H，Wang Z，et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma（2019 edition）［J］. Liver Cancer，2020，9：682-720.
［2］Cerina D，Matkovic V，Katic K，et al. Real-world efficacy and safety of bevacizumab in the first-line treatment of metastatic cervical cancer：a cohort study in the total population of croatian patients［J］. J Oncol，2021，2021：2815623.
［3］Yi M，Zheng X，Niu M，et al. Combination strategies with PD-1/PD-L1 blockade：current advances and future directions［J］. Mol Cancer，2022，21：28.
［4］Sperandio RC，Pestana RC，Miyamura BV，et al. Hepatocellular carcinoma immunotherapy［J］. Annu Rev Med，2022，73：267-278.
［5］章浙伟，郑家平，郭立文，等.TACE联合瑞戈非尼序贯治疗中晚期肝细胞癌的疗效和安全性［J］.介入放射学杂志，2022，31：1198-1202.
［6］Kudo M. Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma［J］. Cancers（Basel），2020，12：1089.
［7］Xue J，Ni H，Wang F，et al. Advances in locoregional therapy for hepatocellular carcinoma combined with immunotherapy and targeted therapy［J］. J Interv Med，2021，4：105-113.
［8］梁军，过欣来，吴迪，等.放射联合介入治疗对肝细胞癌伴门静脉癌栓患者的降期作用研究［J］.肝胆外科杂志，2022，30：253-257.
［9］Zou X，Xu Q，You R，et al. Efficacy and safety of TACE combined with regorafenib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma after sorafenib esistance［J］. J Hepatocell Carcinoma，2023，10：267-279.
［10］Raoul JL，Forner A，Bolondi L，et al. Updated use of TACE rfor hepatocellular carcinoma treatment：how and when to use it based on clinical evidence［J］. Cancer Treat Rev，2019，72：28-36.
［11］庞军，郝光远，陈燕.巨块型肝细胞癌SBRT联合TACE治疗临床观察［J］.中华肿瘤防治杂志，2020，27：658-662.
［12］Zhao Y，Lai J，Liang R，et al. Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma［J］. J Interv Med，2019，2：78-83.
［13］王飞，谢晓鸿，林心情，等.基于真实世界数据对晚期非小细胞肺癌合并慢性阻塞性肺疾病患者治疗模式的探讨［J］.中华结核和呼吸杂志，2020，43：450-454.
［14］Zhao F，Henderson TO，Cipriano TM，et al. The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort［J］. Cancer，2021，127：4072-4080.
［15］Kudo M. Limited impact of Anti-PD-1/PD-L1 monotherapy for hepatocellular carcinoma［J］. Liver Cancer，2020，9：629-639.
［16］Zhu S，Liu C，Dong Y，et al. A retrospective study of lenvatinib monotherapy or combined with programmed cell death protein 1 antibody in the treatment of patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma in China［J］. Front Oncol，2021，11：788635.
［17］丁晓鹏，帖君，余嘉豪，等.TACE联合抗血管生成药及PD-1抑制剂治疗中晚期肝癌的有效性和安全性［J］.肝脏，2022，27：277-280，291.

相似文献/References:

[1]郭建海,杨仁杰.血清nm２３－H１水平对肝细胞肝癌TACE治疗预后的影响[J].介入放射学杂志,2010,(06):463.
　GUO Jianhai,Yang Renjie.Impact of serum nm２３－H１level on the prognosis of hepatocellular carcinoma after transcatheter arterial chemoembolization treatment[J].journal interventional radiology,2010,(09):463.
[2]王有枝,李彦豪,梅雀林,等.原发性肝癌肝动脉化疗栓塞术后继发溶血性尿毒综合征3例并文献复习[J].介入放射学杂志,2016,(06):543.
　WANG You-zhi,LI Yan-hao,MEI Que-lin,et al.Secondary hemolytic uremic syndrome occurring after transcatheter arterial chemoembolization for primary hepatocellular carcinoma: report of 3 cases with literature review [J].journal interventional radiology,2016,(09):543.
[3]蒋健强,李晓娟,李拥军,等.白蛋白-胆红素评分在预测TACE治疗巨块型肝细胞癌后肝功能衰竭中的应用[J].介入放射学杂志,2023,32(01):55.
　JIANG Jianqiang,LI Xiaojuan,LI Yongjun,et al.The application of albumin-bilirubin score in predicting liver failure after transarterial chemoembolization for massive hepatocellular carcinoma [J].journal interventional radiology,2023,32(09):55.
[4]刘　晟,周平盛,沈　强,等.超声引导下微波消融术治疗特殊部位与非特殊部位单发肝细胞癌的疗效对比[J].介入放射学杂志,2023,32(01):36.
　LIU Sheng,ZHOU Pingsheng,SHEN Qiang,et al.Ultrasound-guided microwave ablation for the treatment of single hepatocellular carcinoma located at specific area and at non-specific area: comparison of clinical efficacy[J].journal interventional radiology,2023,32(09):36.
[5]王　曦,冯　苏,李　红,等.免疫检查点抑制剂联合TACE在肝癌治疗中的研究进展[J].介入放射学杂志,2023,32(01):90.
　WANG Xi,FENG Su,LI Hong,et al.Research progress in immune checkpoint inhibitors combined with TACE for the treatment of hepatocellular carcinoma[J].journal interventional radiology,2023,32(09):90.
[6]吴迪,郑琳.载药微球栓塞治疗在肝癌全程管理中的临床应用进展[J].介入放射学杂志,2024,33(08):921.
　WU Di,ZHENG Lin..Application progress of drug-loaded microspheres embolization therapy in the clinical full-process management of hepatocellular carcinoma[J].journal interventional radiology,2024,33(09):921.
[7]陈荔,吴大广,朱光宇,等.经动脉化疗栓塞联合免疫和靶向药治疗Child-Pugh B级肝细胞癌研究[J].介入放射学杂志,2024,33(09):968.
　CHEN Li,WU Daguang,ZHU Guangyu,et al.Transarterial chemoembolization combined with immune checkpoint inhibitor and molecular targeted therapy for Child-Pugh grade B hepatocellular carcinoma[J].journal interventional radiology,2024,33(09):968.
[8]沈晓娣,叶盼,边雪梅,等.基于抑木扶土理论的气交灸联合揿针干预经导管肝动脉化疗栓塞术后疼痛、恶心呕吐的临床研究[J].介入放射学杂志,2024,33(09):1014.
　SHEN Xiaodi,YE Pan,BIAN Xuemei,et al.The“suppressing wood-supporting earth” theory-based air moxibustion combined with pushpin-like needle acupuncture in the treatment of pain，nausea and vomiting after TACE：a clinical study[J].journal interventional radiology,2024,33(09):1014.
[9]张岩基,王汇源,李浩,等.经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展[J].介入放射学杂志,2024,33(09):1039.
　ZHANG Yanji,WANG Huiyuan,LI Hao,et al.Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma[J].journal interventional radiology,2024,33(09):1039.
[10]殷梦杰,付守忠,戴锋,等.肝动脉灌注化疗联合卡瑞利珠单抗及索拉非尼治疗中晚期肝癌的疗效与安全性分析 [J].介入放射学杂志,2024,33(11):1212.
　YIN Mengjie,FU Shouzhong,DAI Feng,et al.Hepatic arterial infusion chemotherapy combined with carrelizumab and sorafenib for the treatment of advanced hepatocellular carcinoma：its clinical efficacy and safety[J].journal interventional radiology,2024,33(09):1212.

备注/Memo

备注/Memo:
（收稿日期：2023-09-25）
（本文编辑：茹实）
更新日期/Last Update: 2024-09-15